Phoenix, AZNCT05836987Now EnrollingIRB Ready

Atrial Fibrillation Clinical Trial in Phoenix, AZ

Access cutting-edge atrial fibrillation treatment through this phase 3 clinical trial at a research site in Phoenix. Study-provided care at no cost to qualified participants.

Sponsored by Johns Hopkins University

Quick Self-Assessment

See if you qualify for this Phoenix location

Preparing your pre-screening questions…

Expert Care in Phoenix

Access atrial fibrillation specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related atrial fibrillation treatment provided free

Apply for This Phoenix Location

Check if you qualify for this atrial fibrillation clinical trial in Phoenix, AZ

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Phoenix

    Convenient for AZ residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Phoenix site if eligible
  4. 4Begin participation

About This Atrial Fibrillation Study in Phoenix

REACT-AF is a multicenter prospective, randomized, open-label, blinded endpoint (PROBE design), controlled trial comparing the current Standard Of Care (SOC) of continuous Direct Oral Anticoagulation (DOAC) use versus time-delimited (1 month) DOAC guided by an AF-sensing Smart Watch (AFSW) in participants with a history of paroxysmal or persistent Atrial Fibrillation (AF) and low-to-moderate stroke risk.

Sponsor: Johns Hopkins University

Who Can Participate

Inclusion Criteria

22-85 years of age.
English speaking participants. Spanish-only speakers may be included in the future at select sites appropriately translated.
History of non-permanent atrial fibrillation.
CHA2DS2-VASC score of 1-4 for men and 2-4 for women without prior stroke or Transient Ischemic Attack (TIA), The CHA2DS2-VASc score is a point-based system used to stratify the risk of stroke in Atrial Fibrillation (AF) patients. The acronym CHA2DS2-VASc stands for congestive heart failure, hypertension, age ≥75 (doubled), diabetes, stroke (doubled), vascular disease, age 65 to 74 and sex category (female). Congestive heart failure defined as: The presence of signs and symptoms of either right (elevated central venous pressure, hepatomegaly, dependent edema) or left ventricular failure (exertional dyspnea, cough, fatigue, orthopnea, paroxysmal nocturnal dyspnea, cardiac enlargement, rales, gallop rhythm, pulmonary venous congestion) or both, confirmed by non-invasive or invasive measurements demonstrating objective evidence of cardiac dysfunction and/or ejection fraction \< 40%.
The participant is on a DOAC at the time of screening and willing to stay on DOAC for duration of study.
Willing and able to comply with the protocol, including:
Possession of a smart watch-compatible smart phone (iPhone that supports the latest shipping iOS) with a cellular service plan
Be willing to wear the smart watch for the suggested minimum of 14 hours a day
Expected to be within cellular service range at least 80% of the time
Willing and able to discontinue DOAC
The participant is willing and able to provide informed consent.

Exclusion Criteria

Valvular or permanent atrial fibrillation.
Current treatment with warfarin and unwilling or unable to take a DOAC.
The participant is a woman who is pregnant or nursing.
The participant is being treated with chronic aspirin, another anti-platelet agent, or chronic NSAIDS outside of current medical guidelines (e.g., primary stroke prevention in patients with atrial fibrillation, primary prevention of cardiovascular events, pain relief, fever, gout) and is unwilling or unable to discontinue use for the study duration.
Existing cardiac rhythm device or indication for a permanent pacemaker, Implantable Cardioverter-Defibrillator (ICD) or Cardiac Resynchronization Therapy (CRT) device or planned insertable cardiac monitor. Insertable cardiac monitors are permitted unless they are being used to guide anticoagulation treatment.
Known or suspected symptomatic or asymptomatic atrial fibrillation lasting ≥ 1 hour/month over the last 3 months.
Any documented single AF episode lasting ≥ 1 hour on standard of care or study-provided external cardiac monitor of \> 6 days duration performed within 45 days prior to randomization. Shorter monitoring durations may be acceptable for inclusion at the discretion of the site PI based on the totality of monitoring data and approval of the study PI.
Ablation for AF within the last 2 months.
Prior or anticipated left atrial appendage occlusion or ligation.
Mechanical prosthetic valve(s) or severe valve disease.
Hypertrophic cardiomyopathy.
Participant needs DOAC for reasons other than preventing stroke or arterial embolism resulting from AF (i.e., preventing Deep Vein Thrombosis (DVT) or PE) or needs permanent OAC (i.e., congenital heart defects, prosthetic heart valve).
Participants deemed high risk for non-cardioembolic stroke (i.e., significant carotid artery disease defined as stenosis \> 75%) based on the investigator's discretion.
The participant is enrolled, has participated within the last 30 days, or is planning to participate in a concurrent drug and/or device study during the course of this clinical trial. Co-enrollment in concurrent trials is only allowed with documented pre-approval from the study manager; there is no concern that co-enrollment could confound the results of this trial.
The participant has a tattoo, birthmark, or surgical scar over the dorsal wrist area on the ipsilateral side that the AFSW may be worn.
The participant has a tremor on their ipsilateral side that the AFSW may be worn.
Any concomitant condition that, in the investigator's opinion, would not allow safe participation in the study (e.g., drug addiction, alcohol abuse).
Known hypersensitivity or contraindication to direct oral anticoagulants.
Documented prior stroke (ischemic or hemorrhagic) or transient ischemic attack.
Reversible causes of AF (e.g., cardiac surgery, pulmonary embolism, untreated hyperthyroidism). AF ablation does not constitute reversible AF.
\> 5% burden of premature atrial or ventricular depolarizations on pre-enrollment cardiac monitoring.
History of atrial flutter that has not been treated with ablation (participants in atrial flutter and have been ablated are eligible for enrollment).
Stage 4 or 5 chronic kidney disease.
Conditions associated with an increased risk of bleeding:
Major surgery in the previous month
Planned surgery or intervention in the next three months that would require cessation of anticoagulation \> 2 weeks.
History of intracranial, intraocular, spinal, retroperitoneal, or atraumatic intra- articular bleeding
Gastrointestinal hemorrhage within the past year unless the cause has been permanently eliminated (e.g., by surgery)
Symptomatic or endoscopically documented gastroduodenal ulcer disease in the previous 30 days
Hemorrhagic disorder or bleeding diathesis
Need for anticoagulant treatment for disorders other than AF
Uncontrolled hypertension (Systolic Blood Pressure \>180 mmHg and/or Diastolic Blood Pressure \>100 mmHg)

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Phoenix?

Yes, this clinical trial (NCT05836987) has an active research site in Phoenix, AZ that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Atrial Fibrillation Treatment Options in Phoenix, AZ

If you're searching for atrial fibrillation treatment options in Phoenix, AZ, this clinical trial (NCT05836987) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Phoenix research site is actively enrolling participants for this phase 3 clinical trial. You'll receive care from experienced atrial fibrillation specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all atrial fibrillation clinical trials near you to find additional studies recruiting in your area.

More Atrial Fibrillation Trials in Phoenix, AZ

See all atrial fibrillation clinical trials recruiting in Phoenix — not just this study.

Browse Atrial Fibrillation Trials in Phoenix →

Browse More Trials by Condition

Atrial Fibrillation TrialsAll Conditions →

Ready to Join in Phoenix?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Phoenix, AZ